Genmab — November 2017
-
line treatment of cervical cancer, Mr Van De Winkel says. • Analysts underestimate Darzalex’s future sales, including Bernstein’s peak sales estimate of USD 10.3bn, the CEO says. • Genmab’s modelling shows drug’s peak sales “north” of that, the CEO says. • Estimates do not take into account Darzalex’s use for multiple myeloma retreatment, maintenance therapy, the CEO says. Source: Bloomberg
-
Myelomatoseforeningen har nu lagt præsentationer fra november-seminaret ud på deres hjemmeside. Den øverste er om car-t og vacc. Desværre kun præsentationer. Videoer af foredragene er lovet og må vel komme senere. https://www.myelomatose.dk/blog/praesentationer-seminar-dmfimf-2017/
-
-
Har checket angående shortselling i genmab ved finanstilsynet og der er 52 meddelelser fra August 2014 til d.d og de fleste mellem 0.5 til 0.7% og en enkelt gang 0.8% som det højeste nogensinde. Der er ikke registreret shortselling før Aug. 2014. Så mon ikke de også denne gang holder sig under de 0.8%. https://oasm.dfsa.dk/uk/searchresult.aspx?t=genmab
-
Tak @StockBull
-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind